RESUMEN
Gravity Probe B, launched 20 April 2004, is a space experiment testing two fundamental predictions of Einstein's theory of general relativity (GR), the geodetic and frame-dragging effects, by means of cryogenic gyroscopes in Earth orbit. Data collection started 28 August 2004 and ended 14 August 2005. Analysis of the data from all four gyroscopes results in a geodetic drift rate of -6601.8±18.3 mas/yr and a frame-dragging drift rate of -37.2±7.2 mas/yr, to be compared with the GR predictions of -6606.1 mas/yr and -39.2 mas/yr, respectively ("mas" is milliarcsecond; 1 mas=4.848×10(-9) rad).
RESUMEN
GABA level and the activity of L-glutamate-1-decarboxylase (GAD) (EC 4.1.1.15) were studied in brains of mice treated with beta-vinyllactic acid, a new, selective and pyridoxal phosphate-independent GAD inhibitor. Valproate and diazepam protected mice against convulsions caused by beta-vinyllactic acid although both anti-epileptic drugs antagonized neither the decrease in GABA concentrations nor the inhibition of GAD observed after treatment with beta-vinyllactic acid alone. Assuming that the anticonvulsant effect measured with both antiepileptics is GABA mediated, these results support the hypothesis of a postsynaptic enhancement of GABAergic transmission by diazepam and valproate.
Asunto(s)
Convulsivantes/antagonistas & inhibidores , Diazepam/farmacología , Lactatos/antagonistas & inhibidores , Convulsiones/inducido químicamente , Ácido Valproico/farmacología , Animales , Encéfalo/efectos de los fármacos , Convulsivantes/toxicidad , Relación Dosis-Respuesta a Droga , Glutamato Descarboxilasa/antagonistas & inhibidores , Lactatos/toxicidad , Masculino , Ratones , Transmisión Sináptica/efectos de los fármacos , Ácido gamma-Aminobutírico/metabolismoRESUMEN
Racemic d,l-baclofen and l-baclofen depressed the patellar, flexor, linguo-mandibular (0.1--30 mg/kg i.v.) and the H-reflex (1--3 mg/kg i.v.) in a dose-dependent fashion. Racemic and l-baclofen partly antagonized electroshock-induced convulsions in mice (30--60 mg/kg p.o.) and depressed the firing rate of nigral cells when applied iontophoretically. d,l-Baclofen and l-baclofen (0.1--3.0 mg/kg i.v.) moderately reduced the blood pressure in cats. Dextrorotatory baclofen, at identical doses was inactive in all these tests. It is concluded that the biological activity of baclofen resides with the l-enantiomer.
Asunto(s)
Aminobutiratos/farmacología , Baclofeno/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Gatos , Relación Dosis-Respuesta a Droga , Masculino , Ratones , Reflejo/efectos de los fármacos , Convulsiones/tratamiento farmacológico , Sustancia Negra/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacosAsunto(s)
Hipolipemiantes/farmacología , Animales , Antioxidantes/farmacología , Benzoatos/farmacología , Clofibrato/análogos & derivados , Clofibrato/farmacología , Ciclización , Grasas de la Dieta/metabolismo , Congéneres del Estradiol/farmacología , Humanos , Absorción Intestinal/efectos de los fármacos , Lipoproteínas/sangre , Metabolismo/efectos de los fármacosAsunto(s)
Amidinas/síntesis química , Hipoglucemiantes/síntesis química , Amidinas/farmacología , Compuestos de Anilina/análisis , Compuestos de Anilina/síntesis química , Animales , Benzazepinas/análisis , Benzazepinas/síntesis química , Glucemia/análisis , Butiratos/análisis , Butiratos/síntesis química , Fenómenos Químicos , Química , Femenino , Hipoglucemiantes/análisis , Hipoglucemiantes/farmacología , Masculino , Modelos Estructurales , Ratas , Tolbutamida/farmacologíaRESUMEN
PIP: Despite the fact that the role of lipids and cholesterol in atherosclerosis has not been totally clarified to the clinician's satisfaction, medicinal chemistry has been very successful in this last decade in showing that a diverse group of compounds is capable of reducing blood lipid levels in many animal species and in humans. The pharmacological basis for the evaluation of many hypolipidemic agents is summarized. The prostaglandins are vasodepressor agents. They inhibit uterine contraction, yet, on the other hand, they increase cardiac output and induce contraction of intestinal smooth muscle. Prostaglandins exhibit marked antilipolytic activity. It has been shown that 0.2 mug/kg/min, of intravenous infusion of prostaglandin E1 produced an increase in serum-free fatty acide levels in the dog. At a 4 times higher rate of infusion, the plasma-free fatty acid concentration was lowered. The pharmacological activities of individual prostaglandins embrace a great variety of biological phenomena. In certain systems their effects are antagonistic. The rationale for the use of estrogens as hypolipidemics is the observation of the low incidence of atherosclerotic heart disease in Caucasian women of childbearing age.^ieng